DBD
Diebold Nixdorf, Incorporated Technology - Software - Application Investor Relations →
Diebold Nixdorf, Incorporated (DBD) closed at $83.81 as of 2026-06-19, trading 74.5% above its 200-week moving average of $48.03. The stock moved further from the line this week, up from 71.0% last week. The 14-week RSI sits at 61, indicating neutral momentum.
Trading volume is running at 0.7x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.38 ratio) is neutral — neither side is clearly dominating.
In 100 weeks of available data, DBD has never crossed below its 200-week moving average. This suggests the stock has maintained a strong long-term uptrend throughout its history.
With a market cap of $2.9 billion, DBD is a mid-cap stock. The company generates a free cash flow yield of 11.2%, which is notably high. Return on equity stands at 11.0%. The stock trades at 2.9x book value.
The company has been aggressively buying back shares, reducing its share count by 55.3% over the past three years.
Over the past 2 years, a hypothetical investment of $100 in DBD would have grown to $218, compared to $139 for the S&P 500. That represents an annualized return of 47.5% vs 17.8% for the index — confirming DBD as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 49.2% compound annual rate, with 2 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: DBD vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices DBD would reach each dislocation threshold.
Dislocation Price Levels
Prices where DBD's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-03-31).
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $72.06 | Unusually cheap — potential buy zone |
| Value | +1σ | $78.48 | Cheap vs. own history |
| Fair Value | +0σ | $86.15 | Historical mean behavior |
| Expensive | -1σ | $95.49 | Expensive vs. own history |
| Deep Expensive | -2σ | $107.09 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from DBD's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
DBD has not crossed below its 200-week moving average in the available data (100 weeks).
Frequently Asked Questions
Is DBD below its 200-week moving average?
No. Diebold Nixdorf, Incorporated (DBD) is currently 74.5% above its 200-week moving average of $48.03. It would need to fall to $48.03 to cross below the line.
What is DBD's 200-week moving average price?
Diebold Nixdorf, Incorporated's 200-week moving average is $48.03 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
Is DBD a good value right now?
Here's what our data says about DBD as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 61. Free cash flow yield is 11.2%. Return on equity is 11.0%. Price-to-book is 2.9x. This is not a buy or sell recommendation — always do your own research.
How does DBD compare to the S&P 500?
Over the past 2 years, $100 invested in DBD would have grown to $218, compared to $139 for the S&P 500. That's 47.5% annualized vs 17.8% for the index. DBD has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19